Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
14 evidence topics · 16 sources
Diagnostic definition: high-risk genotype with nondiabetic kidney disease
“AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of genotyping: definitive for risk alleles, not diagnostic of a specific disease
“Genetic testing is definitive for the presence of APOL1 risk alleles, although the presence of risk alleles is not prognostic or diagnostic of any specific kidney diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, for individuals, genotyping is an important clinical consideration given that the high-risk APOL1 genotypes are associated with significantly increased risk of CKD progression, and genotyping could inform risk stratification and frequency of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: patients in whom APOL1-associated nephropathy should be considered
“A1. APOL1-associated nephropathy should be considered in all patients with kidney disease who have African ancestry, particularly when there is a family history of CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A2. Regardless of ancestry, APOL1-associated nephropathy should be considered in all patients with kidney disease and a family member with a confirmed APOL1 high-risk genotype” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A3. Clinical factors that are relevant to considering APOL1-associated nephropathy include hypertension, nondiabetic nephropathy, and rapid progression of CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A12. APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: testing and kidney biopsy if a treatment becomes available
“C3. If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C4. If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C6. If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misclassification as hypertension-attributed CKD
“Genetic testing for APOL1 in African ancestry patients with nephropathy is currently uncommon. As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many with West African ancestry who have hypertension and kidney disease who were previously labeled as hypertensive nephropathy are now recognized to carry 2 APOL1 risk alleles and have APOL1-contributed kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: principles for APOL1 testing
“At population levels, there is insufficient evidence to guide recommendations for APOL1 routine testing or screening. There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The individual has kidney disease OR is a prospective living kidney donor OR has a relative with an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with FSGS and CKD, APOL1 genotyping can inform prognosis, and early targeted testing for APOL1 genotype in infants and children could make possible early surveillance and intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening of asymptomatic individuals
“Screening of asymptomatic individuals in the US for high-risk APOL1 genotype is not currently recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, individuals with recent West African heritage who have nondiabetic CKD, proteinuria, or a family history of kidney disease may be offered APOL1 screening. All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO 2024 CKD guideline: genetic testing in evaluation of cause
| Test category | Examples | Comment |
|---|---|---|
| Genetic testing | “APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, HNF1B, PKD1, PKD2” | “Evolving as a tool for diagnosis, increased utilization is expected.” |
Genotype refinement: the p.N264K (M1) protective variant
“Therefore, this variant, based on prior functional and current genetic data, counters the toxic effect of the G2 allele, allowing the reclassifying of APOL1 high-risk individuals as non-high-risk if they carry the p.N264K missense variant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with CKD with APOL1-HR genotypes, M1 was 4 times more frequent in those whose CKD was not due to FSGS or SRNS. Importantly, electronic health record and biopsy review identified an alternative, non-APOL1 cause for CKD in nearly all APOL1-HR-M1 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with CKD with an APOL1-HR genotype and M1 should be evaluated for an alternative and potentially treatable cause of their CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mendelian kidney disease in patients with high-risk genotypes
“Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes. Among patients with recent genomic African ancestry, the prevalence of Mendelian kidney diseases was lower in those with high-risk APOL1 genotypes (9.6%; n = 91/944) compared with single risk APOL1 allele carriers (13.6%; n = 198/1453) and those with G0/G0 APOL1 genotypes (16.6%; n = 213/1281).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unexplained kidney failure in the United Kingdom
Living kidney donor evaluation
“Among transplant centers in the United States, in 1 survey,93 one-half of centers offered APOL1 testing. The KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors94 suggests that APOL1 genotyping may be offered to donor candidates with Sub-Saharan African ancestry. The British Transplantation Society95 recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthy living donors who self-identify as Black people or of sub-Saharan or West African ancestry, who are otherwise approved for donation, should be counseled regarding the risk of future kidney disease from APOL1 G1 and G2 variants and the protective role of the N264K APOL1 variant and should also offered the option of testing (Supplementary Information, Case 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study found that the APOL1 genotype is a risk factor for reduced kidney function postdonation. These results suggest that all Black individuals who are living donor candidates in the US should undergo APOL1 genotyping for better risk stratification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote